| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1034/J.1399-3062.2001.00001.X |
| P698 | PubMed publication ID | 11926743 |
| P2093 | author name string | Rubin RH | |
| P2860 | cites work | Human herpesvirus 6. | Q33539466 |
| Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future. | Q34275883 | ||
| Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. | Q34294829 | ||
| Infection in organ-transplant recipients | Q34471508 | ||
| Role of cytomegalovirus in cardiac allograft vasculopathy | Q34583505 | ||
| Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation | Q34583509 | ||
| Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection | Q35160206 | ||
| 9-(1-3-Dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice | Q35540779 | ||
| Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB. | Q38296897 | ||
| Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells | Q41516547 | ||
| High incidence of active cytomegalovirus infection among septic patients | Q43552832 | ||
| Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus | Q43962601 | ||
| Antigenemia in the Diagnosis and Monitoring of Active Cytomegalovirus Infection after Liver Transplantation | Q46106720 | ||
| Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. | Q50649143 | ||
| Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. | Q53346269 | ||
| An unusual complication of cardiac transplantation--infected aortic pseudoaneurysm | Q68204472 | ||
| Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis | Q68249333 | ||
| Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients | Q69807975 | ||
| The protective effects of hyperimmune anti-murine cytomegalovirus antiserum against lethal viral challenge: the case for passive-active immunization | Q70127148 | ||
| Pretransplantation assessment of the risk of lymphoproliferative disorder | Q71910946 | ||
| Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection | Q72940981 | ||
| Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients | Q73340549 | ||
| Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients | Q73398703 | ||
| Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection | Q73434709 | ||
| Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure | Q73824564 | ||
| Cytomegalovirus infection in patients with bacterial sepsis | Q74578341 | ||
| A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients | Q77378215 | ||
| P921 | main subject | Cytomegalovirus | Q6946 |
| organ transplantation | Q69253852 | ||
| P304 | page(s) | 1-5 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Transplant Infectious Disease | Q15749562 |
| P1476 | title | Cytomegalovirus in solid organ transplantation. | |
| P478 | volume | 3 Suppl 2 |
| Q54624695 | Comparison of quantitative PCR and antigenemia in cytomegalovirus infection in renal transplant recipients. |
| Q37070704 | Cytomegalovirus-infected human endothelial cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic exosomes |
| Q37157642 | Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection |
| Q52564748 | Earlier and higher rates of cytomegalovirus infection in pediatric liver transplant recipients as compared to adults: An observational study. |
| Q42366690 | Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies. |
| Q36526167 | Infections in pediatric solid organ transplant recipients |
| Q33347669 | Oral manifestation of cytomegalovirus associated with herpes simplex virus in renal transplant recipient |
| Q55072526 | The Donor Major Histocompatibility Complex Class I Chain-Related Molecule A Allele rs2596538 G Predicts Cytomegalovirus Viremia in Kidney Transplant Recipients. |
| Q93052080 | The Interferon-Gamma +874 A/T Polymorphism Is Not Associated With CMV Infection After Kidney Transplantation |
| Q34261510 | The M33 G protein-coupled receptor encoded by murine cytomegalovirus is dispensable for hematogenous dissemination but is required for growth within the salivary gland |
| Q45399182 | The effect of Epstein-Barr virus infection on medium-term survival after orthotopic heart transplantation |
| Q36302615 | The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies? |
| Q43466246 | Universal prophylaxis with gancyclovir preparation is not necessary in our kidney allograft recipients |
| Q84028040 | [Risk factors for cytomegalovirus in solid organ transplant recipients] |
Search more.